Financials

  • Market Capitalization 542.13 M
  • Employee 50
  • Founded 2019
  • CEO N/A
  • Website www.helus.com
  • Headquarter British Columbia, Canada
  • FIGI BBG00MFNRRT4
  • Industry Biotechnology
Total revenue
Net income
Total debt
Free cash flow
Cash & equivalents

Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
2778
IVA
Inventiva S.A. - American Depository Shares
2.87 USD-8.01%-17.05%-26.41%-39.58%554.59 M USD
2781
STTK
Shattuck Labs, Inc. - Common Stock
5.49 USD-9.85%-4.69%-11.17%+188.95%550.99 M USD
2799
DBVT
DBV Technologies S.A. - American Depositary Shares
9.03 USD-5.45%-7.29%-25.98%-41.48%534.69 M USD
2818
PBYI
Puma Biotechnology Inc - Common Stock
10.12 USD-1.65%+7.09%+10.60%+89.51%522.40 M USD

Frequently asked questions about Helus Pharma Inc. Common Stock

What is the Helus Pharma Inc. Common Stock stock price today?

The current price of Helus Pharma Inc. Common Stock (HELP) is 10.50. Over the past 24 hours, the stock has changed by -4.81%. Follow the HELP chart for real-time price dynamics.

What is the stock ticker of Helus Pharma Inc. Common Stock?

Helus Pharma Inc. Common Stock trades under the ticker HELP. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is Helus Pharma Inc. Common Stock stock going up?

HELP has changed by -1.22% over the last week, -21.93% over the last month, and +17.06% over the last year. Review the chart to see whether the current move is part of a broader trend.

What is the market capitalization of Helus Pharma Inc. Common Stock?

Helus Pharma Inc. Common Stock currently has a market capitalization of 542.13 M. Market capitalization reflects the total market value of a company's outstanding shares and is commonly used to compare companies by size.

How many employees does Helus Pharma Inc. Common Stock have?

As of the latest available data, Helus Pharma Inc. Common Stock has 50 employees. Workforce size can provide additional context about the company's scale and operations.

How can I buy Helus Pharma Inc. Common Stock stock?

You can buy Helus Pharma Inc. Common Stock (HELP) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in Helus Pharma Inc. Common Stock stock?

Investing in Helus Pharma Inc. Common Stock requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the HELP chart and related analysis on metatrader.com as part of your research.

Cybin Inc. - Common Stock

Helus Pharma, also known formerly as Cybin IRL, is a Canadian pharmaceutical company that was led by CEO Doug Drysdale from 2020-2025, developing psychedelic drugs as medicines. The company's drug candidates include psilocybin, HLP002, deupsilocin, deudimethyltryptamine, HLP005, and HLP006. Another drug that the company has developed is CYB210010. As of January 2025, deupsilocin is in phase 3 clinical trials. The drug is one of the only other psychedelics besides Compass Pathways's COMP360 to have reached this late stage of clinical development. In 2020, Helus Pharma acquired psychedelic pharmaceutical company Adelia Therapeutics. In late 2023, it acquired Small Pharma, the developer of SPL026 and SPL028. Helus Pharma was originally known as Cybin but changed its name in December 2025.